Head-To-Head Comparison: Mazor Robotics (MZOR) vs. Its Peers
Mazor Robotics (NASDAQ: MZOR) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Mazor Robotics to related companies based on the strength of its dividends, valuation, risk, institutional ownership, earnings, analyst recommendations and profitability.
This table compares Mazor Robotics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mazor Robotics Competitors||-330.23%||-33.54%||-12.51%|
This is a summary of recent ratings for Mazor Robotics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mazor Robotics Competitors||416||2180||3387||122||2.53|
Mazor Robotics currently has a consensus price target of $36.60, suggesting a potential downside of 18.12%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 20.82%. Given Mazor Robotics’ higher probable upside, equities research analysts clearly believe Mazor Robotics is more favorable than its peers.
Insider and Institutional Ownership
27.5% of Mazor Robotics shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Mazor Robotics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mazor Robotics||$48.85 million||-$18.28 million||-56.58|
|Mazor Robotics Competitors||$2.02 billion||$430.37 million||-56.73|
Mazor Robotics’ peers have higher revenue and earnings than Mazor Robotics. Mazor Robotics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Mazor Robotics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Mazor Robotics’ peers have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.
Mazor Robotics peers beat Mazor Robotics on 8 of the 12 factors compared.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.